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Abstract
Objective—To investigate risk for language impairment in children perinatally infected or
exposed to HIV.
Methods—We evaluated the prevalence of language impairment (LI) in 7–16 year old children
with perinatal HIV infection (HIV+) compared to children HIV-exposed and uninfected (HEU),
using a comprehensive standardized language test (CELF-4). LI was classified as primary LI (Pri-
LI) (monolingual English exposure and no cognitive or hearing impairment), concurrent LI (Con-
LI) (cognitive or hearing impairment), or no LI. Associations of demographic, caregiver, HIV
disease and antiretroviral treatment (ART) factors with LI category were evaluated using
univariate and multivariable logistic regression models.
Results—Of 468 children with language assessments, 184 (39%) had LI. No difference was
observed by HIV infection status for overall LI or for Pri-LI or Con-LI; mean (SD) CELF-4 scores
were 88.5 (18.4) for HIV+ vs 87.5 (17.9) for HEU. After adjustment, Black children had higher
odds of Pri-LI vs no LI (aOR=2.43, p=0.03). Children who were Black, Hispanic, had a caregiver
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with low education or low IQ, or a non-biological parent as caregiver had higher odds of Con-LI
vs no LI. Among HIV+ children, viral load >400 copies/ml (aOR=3.04, p<0.001), CDC Class C
(aOR=2.19, p=0.02) and ART initiation <6 months of age (aOR=2.12, p=0.02) were associated
with higher odds of Con-LI vs. no LI.
Conclusions—Children perinatally exposed to HIV are at high risk for LI, but such risk was not
increased for youth with HIV. Risk factors differed for Pri-LI and Con-LI.
Keywords
Pediatric HIV infection; language impairment; antiretroviral therapy
INTRODUCTION
Children perinatally-infected with Human Immunodeficiency Virus (HIV) are at risk for
impairments in cognitive functioning1–2. Increased risk for language impairment is also
reported, which can affect academic performance or adherence to medication3–6. Impaired
verbal functioning has been shown to be associated with HIV disease progression7 and
greater immunosuppression8. In a sample of children infected with HIV who were evaluated
prior to the availability of antiretroviral (ARV) drug therapy, the prevalence of language
impairment (LI) was 10%9. Treatment with one or two nucleoside reverse transcriptase
inhibitors (NRTIs) in the pre-HAART (highly active antiretroviral therapy) era has been
associated with improvement, though not normalization, of overall cognitive and specific
language measures in some studies5,10. However, Wolters et al found that over the course of
a 24-month ART regimen, cognitive abilities remained stable while language abilities
continued to decline, suggesting differential effects on specific brain functions8. Initiation of
HAART has been associated with stabilization in measures of overall cognitive and
language function11–14. However, studies focused on assessment of language function in
school-aged children in the HAART era are lacking.
It is not clear if language impairments in children with HIV infection are indications of a
global developmental impairment, including non-verbal and verbal intelligence, or whether
language impairment can be a selective deficit. Another possible source of language
impairment is related to risk for hearing loss, possibly as a consequence of mitochondrial
dysfunction. Prior studies suggest that HIV and its treatment are associated with
mitochondrial dysfunction15 and it has been demonstrated that mitochondrial dysfunction/
mutation is associated with sensorineural hearing loss16–17.
In healthy children without HIV exposure, language impairments appear in children whose
general cognitive abilities are well within or even above age expectations. The condition of
Specific Language Impairment (SLI) is defined as language impairments without other
developmental impairments. In a study of 7,218 kindergarten children to determine the
prevalence of SLI, Tomblin et al18 reported 7.4% with SLI and 12% of the children with
language sparing, children who scored low on nonverbal IQ assessment (in the range of 70–
87) but demonstrated language performance within normal limits19, suggesting a
dissociation of language acquisition and nonverbal intelligence. Similarly, Rice et al20
documented that children with low nonverbal IQ levels can have grammatical skills within
or above typical levels. On the other hand, children who have both language impairments
and nonverbal cognitive impairments scored lower, and grew more slowly in language skills
between 6 and 10 years, than children with SLI. In effect, language impairments are not
necessarily part of a global developmental impairment in healthy children but if both
language and cognition are low, the combination yields lower language performance than
language impairment alone, and slower growth over time. The prevalence of speech or
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language impairments among children is relatively high and comprises a high proportion of
children who receive special education services at school entry (62%)21. This diagnosis has
a reciprocal relationship to services for children with learning disability. In kindergarten,
11% of children with special education services are characterized as having learning
disabilities, whereas in 5th grade, the age level for many of the children in this study, 60% of
children receiving special education services are diagnosed with learning disabilities and the
percent of children receiving services for speech or language impairment drops to 14%21.
The shift seems to be related to a high risk of reading impairment in children with early
language impairments, with later diagnosis of reading impairments22. The diagnosis of
language impairment tends to occur at a younger age than that of reading impairment, and
the later reading impairment is identified in academic tasks and targeted as a priority for
remediation, even though the language impairments are likely to persist23. Children exposed
to or living with HIV who have language impairments may be at risk for poor or delayed
academic achievement3.
Understanding the sources of low performance on language assessments in children with
HIV or under HAART treatment for HIV requires differentiation of language impairments
associated with cognitive impairments, or as a consequence of hearing impairment. Here we
adopt the terminology of Primary impairment (Pri-LI) for children with language
impairments with no other known impairments24, versus Concurrent impairment, (Con-LI,
sometimes referred to as “Secondary LI”24), for children with language impairment along
with possible hearing and/or cognitive impairment25. Children with HIV could be at higher
risk for these concurrent impairments due to the ongoing or intermittent exposure of the
developing brain to chronic immune dysregulation that characterizes HIV infection, or due
to HIV treatment or other complications of HIV disease. Alternatively, risk for Pri-LI could
be increased as a result of HIV infection or other environmental influences that can impair
language acquisition. Comparison of the prevalence and risk factors for LI in children with
HIV infection as compared to those perinatally HIV-exposed but HIV-uninfected can clarify
whether an increased risk of LI is attributable to HIV infection.
Evaluation of risk factors for language impairment, both Pri-LI and Con-LI, is needed to
identify possible contributions of HIV disease, disease severity and treatments, while
controlling for demographic and caregiver characteristics26. This study evaluated the
relationship between language ability and nonverbal cognitive ability, and the prevalence of
Pri-LI and Con-LI in children perinatally infected with HIV (HIV+) compared to children
exposed and uninfected (HEU), and the relationships of HIV-disease characteristics along
with environmental risk factors on language impairment.
METHODS
Study Population
This investigation used data collected in the Adolescent Master Protocol (AMP), a
component of the Pediatric HIV/AIDS Cohort Study (PHACS). AMP is a prospective cohort
study conducted at 15 sites in the United States, including Puerto Rico, designed to evaluate
the impact of HIV infection and ART on the development of children and adolescents with
perinatal HIV exposure. The study protocol was approved by the institutional review board
(IRB) of each participating site; written informed consent was obtained from each child’s
parent/legal guardian or from older participants as allowed by the local IRB. Written assent
was obtained as appropriate. The study opened to enrollment in March 2007.
Children ages 7–16 years born to women with HIV infection were eligible. The study design
included both children infected with HIV (HIV+) and children exposed and uninfected
(HEU). At each semi-annual study visit, information about study participants and their
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families was gathered through clinical interviews, medical record reviews, and
neurodevelopmental testing. The current study is a cross-sectional analysis of language data
collected at the first six-month follow up visit, the first time language was assessed. Lifetime
health and treatment histories were obtained through chart reviews and current health status
was ascertained through physical and laboratory evaluations.
Assessment of Language Impairment
Language functioning was evaluated using the comprehensive Clinical Evaluation of
Language Functioning-Fourth Edition (CELF-4)27. Language Impairment (LI) was defined
as scoring more than one standard deviation (SD) below the reference mean (CELF-4 Core
Language Standard Score less than 85, equivalent to the 16th percentile). This criterion was
motivated by the observation that the norming samples for CELF-4 (reported in the test
manual, p. 207) included children from bilingual homes (15%) as well as children receiving
special services (9.5% overall, 4.8% for learning disability or intellectual disability, and
7.0% for speech or language services). Further, the criterion of one standard deviation below
the mean is commonly used in studies of children with SLI, allowing comparison across
studies28.
The age range of the AMP study crosses two versions of the CELF-4 protocol. Children
ages 7 and 8 years completed the following subtests: Concepts and Following Directions;
Word Structure, Recalling Sentences, and Formulated Sentences. Children ages 9 and older
completed these subtests: Concepts and Following Directions, Recalling Sentences,
Formulated Sentences, Receptive Word Classes and Expressive Word Classes. The Core
Language Standard Score was computed for the age appropriate subtests, yielding a
comparable standard score across age levels.
LI was classified as Pri-LI (LI with no cognitive or hearing impairment) or Con-LI (LI with
cognitive or hearing impairment). Audiometric hearing examinations or hearing screens
were requested according to the study protocol for children who scored in the LI range; 72%
of those with LI received audiometric exams, 7% received routine hearing screenings, and
21% had a caregiver report of presence or absence of permanent hearing loss or concerns
regarding the child’s hearing. In some cases caregiver reports were based on prior
audiometric exams. Nonverbal cognitive impairment was defined as a standard score less
than 85, one standard deviation below the mean (< −1 SD), on the Perceptual Reasoning
Index (PRI) of the Wechsler Intelligence Scale for Children-Fourth Edition (WISC-IV)29.
The possible confounding effect of multilingual exposure on LI was considered. For those
children administered the CELF-4 in English, multilingual exposure was defined as
exposure to non-English language either at home or outside the home. The CELF-4 (as well
as the WISC-IV) was given in Spanish to children whose primary language was Spanish,
based on parent report and/or examiner judgment. For these children, exposure to other
languages was not collected and they were classified as monolingual. For the analyses of
Pri-LI and Con-LI, children with LI who also had multilingual exposure could not be
classified as Pri-LI; they were classified as Con-LI only if they met the criteria for cognitive
or hearing impairment. See further detail in the Results section.
Assessment of Other Risk Factors for Language Impairment
The ART regimen at the time of CELF administration was determined from medication
regimen data collected in AMP. Age at ART initiation was based on the earliest date of
ARV use, excluding neonatal prophylaxis in the first two months of life and treatment
durations less than a week, determined by review of individual records. HIV viral load and
CD4+ T-lymphocyte count and percent, two widely used indicators of HIV disease severity
(see guidelines at http://aidsinfo.nih.gov/contentfiles/Pediatric_Guidelines.pdf) were
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obtained as part of routine medical care; results closest to the CELF administration were
used in our analysis. Current or past diagnosis with an AIDS-defining condition was based
on CDC clinical classification, determined by pediatric surveillance definitions for
participants younger than 13 years of age (1994) and the revised adult case definition of
AIDS-defining conditions for participants 13 years of age or older (1993).
Factors widely considered as predictors of children’s language acquisition were also
evaluated as potential confounders in our analysis. Caregiver’s education (low level defined
as less than high school degree), household income (low level defined as <$20,000 annual
income), marital status, and relationship to child (biological parent or other) are potential
influences on children’s development30 although environmental prediction of language
impairments has yielded mixed outcomes in large population samples31. These variables
were obtained by caregiver self-report at study entry. Maternal ARV drug use during
pregnancy was obtained at entry in PHACS or from previous studies in which the child and/
or mother participated. Caregiver’s performance IQ (PIQ) was included as an index of
nonverbal cognitive functioning, obtained by direct assessment with the Wechsler
Abbreviated Scale of Intelligence, with impairment defined as <7032.
Statistical Methods
The relationship of language and nonverbal intelligence across the full sample was
examined based on Pearson correlation coefficients and inspection of bivariate distributions.
Children in the HIV+ and HEU groups were compared with respect to demographic and
caregiver characteristics. The prevalence of Pri-LI, Con-LI, and no LI was summarized by
demographic and caregiver characteristics, and by HIV disease characteristics among the
children with HIV. T-tests or ANOVAs and Fisher’s Exact tests were used to compare
characteristics between HIV+ and HEU groups and across language impairment categories,
as appropriate. Univariate and multivariable logistic regression models were used to
evaluate the association of HIV status and other factors with the presence of Pri-LI and Con-
LI, each versus No LI, both overall and within the HIV+ group. Risk factors considered for
the HIV+ group also included measures of HIV disease severity. Initial multivariable models
included all covariates with p<0.20 in univariate models. To be as inclusive as possible, final
adjusted models retained all covariates with p<0.15. Because of the specific interest in
evaluating the association of HIV infection status with LI, this variable was included in all
of the models for the overall population.
To provide additional power for detecting differences in language functioning by HIV
infection status, sensitivity analyses were conducted by considering the continuous CELF
scores and comparing the HIV+ to HEU group using linear regression models adjusted for
other confounders. These models were fit with and without child cognitive impairment to
address scientific interest in primary versus concurrent impairment. Analyses were
conducted using SAS Version 9 (SAS Institute, Cary, NC), and were based on data
submitted as of March 1, 2010.
RESULTS
A total of 468 children (306 HIV+ and 162 HEU) had a valid and complete language
assessment, at a median age of 12 years (range 7–16); the children were 52% male, 69%
Black and 26% Hispanic. Table 1 displays demographic and caregiver characteristics by
HIV infection status for the 437 children in whom Pri-LI, Con-LI and no LI could be
distinguished (excluding 8 children due to missing WISC-IV PRI scores and 23 children
with LI and multilingual exposure but no other concurrent hearing or nonverbal cognitive
impairment). The children with HIV in our study were more likely to be older, female,
Black, and non-Hispanic than HEU children. While there were no significant differences in
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most caregiver characteristics (education, marital status, or performance IQ) between the
HIV+ and HEU groups, children with HIV were less likely to be from a low income
household and to have their biological parent as their caregiver. As expected, children with
HIV were less likely to have been exposed to ARV drugs in utero, as compared to children
in the HEU group (18% vs. 85%).
Most children (93%) were administered the CELF-4 in English. Of the 437 children, 153
(35%) scored more than one SD below the general population mean on the CELF-4 Core
Language Score (CELF < 85). The rates of LI were comparable between the HIV+ and the
HEU groups (34% vs 37% respectively) and the mean Core Language scores were also
similar (88.5 vs 87.5). Overall, 32 children (7%) had hearing impairment, 88 (19%) had
multilingual exposure, and 137 (29%) had low nonverbal cognitive scores (<85).
Among the 437 children for whom LI category could be identified 48 (11%) had Pri-LI and
105 (24%) had Con-LI. Concurrent conditions for the children with Con-LI included a low
nonverbal cognitive score for 94 (90%), hearing impairment for 20 (19%) and both low
nonverbal cognitive score and hearing impairment for nine (9%). Multilingual exposure was
present in combination with either low nonverbal cognitive score or hearing impairment for
18 (17%). Of the children without LI, 43 (15%) had low nonverbal cognitive score, 12 (4%)
had abnormal hearing, and 47 (17%) had multilingual exposure. One child (<1%) of the 284
without LI had both a low nonverbal cognitive score and hearing impairment.
The percent within each language impairment category by HIV infection status and
demographic factors is summarized in Table 2. The prevalence of Pri-LI and Con-LI were
similar in the HIV+ and HEU groups, with 10% vs 12% for Pri-LI, and 24% vs 25% for
Con-LI, respectively. The mean CELF-4 Core Language standard scores were highest for
those with no LI (98.7) and slightly higher for those with Pri-LI as compared to Con-LI
(74.2 vs 65.8). The Pearson correlation between nonverbal IQ and CELF Core Language
Standard Scores was 0.63 among all subjects, but higher for those with Con-LI (0.51) and
those with no language impairment (0.37) than for children with Pri LI (0.29). Most children
had consistent levels of nonverbal IQ and language functioning, with 54% scoring above 85
for both the nonverbal WISC and CELF-4 and 24% scoring below 85 for both (i.e., Con-LI).
However, 91 children (21%) had inconsistent measures of functioning, with 11% showing
only language deficits and 10% observed with normal language functioning but low
nonverbal IQ. These inconsistencies in the general continuum of severity motivate separate
evaluation of predictor relationships for Con-LI and Pri-LI, to examine possible differences
between the two groups of children with LI.
A summary of HIV disease severity by language impairment group is provided in Table 3
and illustrated in Figure 1. Children with Con-LI were significantly more likely than those
with Pri-LI or no LI to have initiated ART by 6 months of age, to have a prior CDC Class C
diagnosis, a detectable viral load, and CD4% < 25%. Most children were on HAART with
protease inhibitor (PI) at the six-month visit (72%) with no differences in ART regimen by
LI group.
Table 4 summarizes the results of univariate and final adjusted multivariable logistical
regression models for Pri-LI vs no impairment, both overall (upper panel) and within the
group of children with HIV (lower panel). For the overall study population, the final
adjusted model indicated no significant difference in the odds of Pri-LI vs No LI for HIV+
as compared to HEU groups of children; however, children who were Black had over twice
the odds of Primary LI vs. no LI (aOR=2.43, p=0.03).
Table 5 presents the results of analogous models for Con-LI vs no LI groups, again both
overall (upper panel) and within the group of children with HIV (lower panel). Univariate
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logistic models for Con-LI versus No LI among HIV + and HEU revealed a significant
effect of caregiver education (p=0.01) and a marginal effect of low caregiver nonverbal IQ
(p=0.06), but no significant association with HIV status or other characteristics. However, in
the final adjusted model, a significant increase in the odds of Con-LI was observed for
children who were Black (aOR=3.7, p=0.003) or Hispanic (aOR=3.2, p=0.01), who had a
less educated caregiver (aOR=1.8, p=0.04) or a caregiver with low cognitive score
(aOR=3.3, p=0.05) or had a caregiver who was not the biological parent (aOR=1.9, p=0.02).
There was no significant effect of HIV infection status on odds of Con-LI vs no LI.
In a sensitivity analysis based on the continuous CELF-4 scores reported in Table 6, linear
regression models indicated no difference in adjusted mean scores between HIV+ vs HEU
(mean difference =0.44, 95% CI: −3.20, 4.08, p=0.81). However, participants of Black race
had an adjusted mean CELF-4 score which was 6.3 points lower than those of non-Black
race (p=0.002), and those of lower socioeconomic status had lower mean scores, as reflected
by having a caregiver without high school education (4.9 points lower, p=0.02) and an
annual household income below $20,000 (3.4 points lower, p=0.06). In addition, low
caregiver cognitive score based on PIQ<70 was associated with significantly lower adjusted
mean scores (10.0 points lower, p=0.04). Further adjustment for child’s cognitive level led
to slight attenuation of differences in adjusted means noted above, but race, caregiver
education, and low caregiver nonverbal IQ remained significantly associated with CELF-4
scores while HIV status remained clearly non-significant (mean difference=0.8, p=0.62).
Within the HIV+ group, univariate and adjusted logistic regression models investigating
disease severity measures are summarized in Table 4 (bottom panel) for Pri-LI vs no LI and
Table 5 (bottom panel) for Con-LI vs no LI. In univariate models, none of the disease
measures reached statistical significance for predicting the odds of Pri-LI vs no LI. In the
multivariate model, only age at ART initiation reached significance indicating a two-fold
increase in odds of Pri-LI for those with later ART initiation. In contrast, those with
detectable viral load, prior CDC Class C diagnosis, or earlier ART initiation had two to
three-fold higher odds of Con-LI vs no LI. Within the HIV+ subgroup, children who were
male or had a biological parent as caregiver had significantly lower odds of Con-LI, while
those who were Black or had a caregiver with lower education had significantly higher odds.
Although children with HIV with lower CD4% (<25%) had significantly increased odds of
Con-LI in univariate models, this association did not persist after adjustment for other
measures of HIV disease severity. Similarly, in sensitivity analyses based on linear
regression models for the continuous CELF-4 score restricted to participants with HIV, only
HIV viral load>400 copies/mL and CDC Class C were associated with lower mean CELF
scores (5.8 and 4.3 points lower, respectively).While children with low CD4% had
marginally lower mean scores in unadjusted models, this finding did not persist after
adjustment for viral load and CDC Class. After further adjustment for child’s nonverbal IQ,
CDC Class C was no longer associated with CELF scores, but child’s nonverbal IQ was
associated with a 19.1 point lower adjusted mean CELF-4-4 score (see Table 6).
DISCUSSION
Language impairment in this cohort was common among children in both HIV+ and HEU
groups, with impairment observed among almost 40% of participants as compared to an
expected rate of 16% in the US population27. The elevated risk is especially noteworthy
given that recent studies note that the practice of including children with language
impairments in the norming data of tests such as CELF-4 reduces test sensitivity for
identifying children with language impairments33. The rate of LI was similar for children in
HIV+ and HEU groups, both overall and within sub-classifications of Pri-LI or Con-LI. The
rates of LI in this study are higher than the rates of LI reported in other studies. For example,
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the overall prevalence of SLI, psychometrically defined similarly to Pri-LI, was 7.4% in a
study of healthy five- to six-year-old children18. Prevalence of SLI for urban African-
American children and for primarily urban Hispanic children (both groups were primarily
low SES) in that study was 11% and 8%, respectively. An additional 5% of the cohort
demonstrated low nonverbal cognitive functioning accompanied by language impairment,
while 12% performed at low nonverbal cognitive levels (70–87 IQ) without language
impairment19. In our study, we found that 10% of the children without LI had low nonverbal
cognitive scores (<85). Low nonverbal cognitive abilities thus could occur with or without
accompanying language impairment and vice-versa.
Results from the logistic regression models indicate that factors predictive of LI differ for
Pri-LI and Con-LI, yet risk of both types of LI was not different for children in HIV+ and
HEU groups. The risk factors examined in these analyses revealed very little about the
sources of risk for Pri-LI in children perinatally exposed to HIV. Other studies report genetic
linkage and association for SLI 28,34–35, suggesting that genetic influences may contribute to
risk in the children exposed to HIV. In the HIV+ and HEU groups of children in this sample,
the established demographic and psychosocial risk factors for Con-LI were notably elevated
relative to reference norms. For the HIV+ group, markers of greater disease severity and
poorer current control were additional risk factors for Con-LI, suggesting that the HIV
disease process may produce more global impairments as seen in Con-LI; the lack of
association of these measures with Pri-LI suggests that advanced HIV disease is less likely
to cause language impairment in isolation. It is notable that 25 of the 59 children with CDC
Class C diagnoses had prior reported diagnoses of encephalopathy36–37. It is also possible
that the smaller number of children with Pri-LI reduced power to detect associations;
however, a sensitivity analysis for the continuous CELF-4 scores offered some confirmation
of this finding in that few HIV disease severity measures were associated with mean
CELF-4 scores after adjustment for children’s low nonverbal cognitive status, akin to lower
mean CELF-4 scores not explained by children’s cognitive status. With approximately 275
HIV+ and 150 HEU subjects, the linear regression approach had 80% power to detect
differences of 4.3 points or more in mean CELF-4 scores.
Age at initiation of ART was associated with both Pri-LI and Con-LI but the effect was in
opposite directions. Early ART was associated with higher odds of Con-LI, but significantly
lower odds of Pri-LI. The negative effects of HIV infection on the central nervous system
can occur prior to birth and during infancy38, before many of the participants in this study
initiated ART. Though current guidelines recommend routine treatment from early infancy,
our study population consisted primarily of older children born at a time when they would
have more likely initiated ART early if they manifested neurologic impairment and other
serious HIV-related disease in infancy. Thus, ART initiation before 6 months of age may be
associated with Con-LI because it is a marker for those children who experienced more
severe neurologic involvement from an early age. Among children who did not exhibit overt
neurologic problems in infancy, subclinical brain involvement was nonetheless likely. For
these children, early ART may have limited or prevented development of
neurodevelopmental problems like Pri-LI, while later initiation of ART ensured survival but
may have permitted a longer pre-treatment period of HIV-related effects on brain function
that placed them at higher risk for more subtle or focused problems, such as Pri-LI. On the
other hand, early ART in the current study may reflect early and perhaps more consistent
access to comprehensive medical and psychological care and support, including referrals to
appropriate early intervention and special education services if delays or deficits are
recognized early. There may also be uncontrolled confounding by disease, treatment or
temporal factors associated with age at ART initiation that underlie these associations, but
none were evident in the current analysis. Early identification of HIV infection with routine
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initiation of HAART in young infants in the United States, as currently recommended and
practiced, may result in different language outcomes in future cohorts.
We did not identify an association between current ART with increased risk of either
Primary or Concurrent LI among youth with perinatal HIV. However, our ability to detect
associations may have been limited by the relatively small percentage of youth not receiving
HAART. Additionally, the majority of children were fairly HAART-experienced (86% had
over 5 years of HAART) which limited our ability to distinguish language functioning by
duration on HAART. Despite widespread HAART use in our study population, 46% of
those with Con-LI had viral load >400 copies/mL, suggesting adherence difficulties or the
possibility of drug resistance. Detectable viral load at the time of language testing was
associated with significantly higher odds of language impairment concurrent with hearing
and/or low nonverbal cognitive scores. This finding suggests that effectiveness of HAART
in reducing deficits in language functioning observed in the pre-HAART era may depend on
careful monitoring of both adherence and resistance patterns to guide optimal therapy.
There were some limitations of our study. Our analysis was a cross-sectional evaluation of
language functioning at a single time point. Future longitudinal follow-up of these children
is necessary to determine the persistence of Pri-LI and Con-LI and possible long-term risks
associated with disease status, treatment, and other risk factors. In addition, despite attempts
to enroll a comparable control group of uninfected children, the HEU children tended to be
younger and living in lower income households. While adjustment for these factors
addressed these imbalances to the extent possible, this illustrates the difficulty of identifying
a comparable control group of children with perinatal HIV exposure. In addition, we were
unable to obtain formal audiometric exams on all children with hearing impairment.
Nevertheless, to our knowledge, this is the first study which specifically addresses hearing
impairment in evaluation of language functioning among children with HIV. The major
strengths of this study include the focus on language impairment, particularly with respect to
its classification into Primary and Concurrent groups, the relatively large sample size, the
use of a group of HEU children for comparison, and the ability to control for potential
confounders.
Several conclusions apply to clinical practice. Physicians providing primary and specialty
care to children perinatally exposed to HIV need a heightened awareness of the high rates of
LI among children of mothers with HIV, interactions between the disease and its treatment,
and routine preventive screening, including hearing assessments. Although Con-LI may be
more salient and readily ascertained, children without cognitive problems with HIV
infection and children exposed but uninfected experience Pri-LI that may be equally
impairing but less easily recognized. Ongoing studies of LI are needed for children with
HIV as temporal changes in antiretroviral therapy may lead to different patterns of LI in the
future. Those providing care to children and youth growing up with perinatal HIV infection
or exposure to HIV should be aware of their substantial risk of LI and potential for
difficulties in school and careers that such impairments may produce. Early and ongoing
intervention could reduce the negative impact of language impairment.
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Figure 1.
Percent with Certain Indicators of HIV Disease Severity among Perinatally HIV-infected
Children within each Language Impairment Category, with 95% Confidence Intervals.
Rice et al. Page 13
J Dev Behav Pediatr. Author manuscript; available in PMC 2013 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Rice et al. Page 14
Ta
bl
e 
1
D
em
og
ra
ph
ic
 c
ha
ra
ct
er
is
tic
s a
nd
 L
an
gu
ag
e 
Im
pa
irm
en
t C
at
eg
or
y 
by
 H
IV
 S
ta
tu
s f
or
 4
37
 H
IV
-in
fe
ct
ed
 o
r H
IV
-E
xp
os
ed
 b
ut
 U
ni
nf
ec
te
d 
C
hi
ld
re
n 
in
 th
e
A
do
le
sc
en
t M
as
te
r P
ro
to
co
l o
f t
he
 P
ed
ia
tri
c 
H
IV
/A
ID
S 
C
oh
or
t S
tu
dy
H
IV
 S
ta
tu
s
C
ha
ra
ct
er
is
tic
1
H
IV
+
(N
 =
 2
84
)
H
E
U
(N
 =
 1
53
)
T
ot
al
(N
 =
 4
37
)
P-
V
al
ue
2
C
E
L
F 
Sc
or
e
M
ea
n 
(S
D
)
88
.5
 (1
8.
4)
87
.5
 (1
7.
9)
88
.1
 (1
8.
2)
0.
57
L
an
gu
ag
e 
Im
pa
ir
m
en
t
Pr
im
ar
y
29
 (1
0%
)
19
 (1
2%
)
48
 (1
1%
)
0.
71
C
on
cu
rr
en
t
67
 (2
4%
)
38
 (2
5%
)
10
5 
(2
4%
)
N
on
e
18
8 
(6
6%
)
96
 (6
3%
)
28
4 
(6
5%
)
A
ge
 (y
ea
rs
)
M
ea
n 
(S
D
)
12
.6
 (2
.6
)
11
.0
 (2
.5
)
12
.0
 (2
.7
)
<0
.0
01
7 
– 
8
31
 (1
1%
)
43
 (2
8%
)
74
 (1
7%
)
<0
.0
01
9 
– 
12
12
0 
(4
2%
)
80
 (5
2%
)
20
0 
(4
6%
)
13
 –
 1
6
13
3 
(4
7%
)
30
 (2
0%
)
16
3 
(3
7%
)
B
ir
th
 Y
ea
r
B
ef
or
e 
19
95
10
9 
(3
8%
)
22
 (1
4%
)
13
1 
(3
0%
)
<0
.0
01
19
95
–1
99
9
14
5 
(5
1%
)
84
 (5
5%
)
22
9 
(5
2%
)
20
00
 a
nd
 L
at
er
30
 (1
1%
)
47
 (3
1%
)
77
 (1
8%
)
M
al
e
13
4 
(4
7%
)
87
 (5
7%
)
22
1 
(5
1%
)
0.
06
R
ac
e
W
hi
te
 o
r O
th
er
56
 (2
0%
)
53
 (3
5%
)
10
9 
(2
5%
)
0.
00
2
B
la
ck
 o
r A
fr
ic
an
 A
m
er
ic
an
21
4 
(7
5%
)
97
 (6
3%
)
31
1 
(7
1%
)
H
is
pa
ni
c 
or
 L
at
in
o 
E
th
ni
ci
ty
54
 (1
9%
)
49
 (3
2%
)
10
3 
(2
4%
)
0.
00
3
C
ar
eg
iv
er
 N
ot
 H
ig
h 
Sc
ho
ol
 G
ra
du
at
e
66
 (2
3%
)
39
 (2
5%
)
10
5 
(2
4%
)
0.
64
A
nn
ua
l H
ou
se
ho
ld
 In
co
m
e 
≤ 2
0K
12
1 
(4
3%
)
97
 (6
3%
)
21
8 
(5
0%
)
<0
.0
01
C
ar
eg
iv
er
 M
ar
ri
ed
11
1 
(3
9%
)
51
 (3
3%
)
16
2 
(3
7%
)
0.
25
C
ar
eg
iv
er
 is
 B
io
lo
gi
ca
l P
ar
en
t
11
9 
(4
2%
)
12
4 
(8
1%
)
24
3 
(5
6%
)
<0
.0
01
C
ar
eg
iv
er
's
 W
A
SI
 P
er
fo
rm
an
ce
 IQ
N
21
9
11
2
33
1
M
ea
n 
(S
D
)
92
.9
 (1
4.
9)
90
.9
 (1
4.
3)
92
.2
 (1
4.
7)
0.
25
Im
pa
irm
en
t (
IQ
 <
70
)
7 
(2
%
)
8 
(5
%
)
15
 (3
%
)
0.
16
M
at
er
na
l A
R
V
 u
se
 in
 p
re
gn
an
cy
50
 (1
8%
)
13
0 
(8
5%
)
18
0 
(4
1%
)
<0
.0
01
C
EL
F=
 C
lin
ic
al
 E
va
lu
at
io
n 
of
 L
an
gu
ag
e 
Fu
nc
tio
ni
ng
; W
A
SI
=W
ec
hs
le
r A
du
lt 
Sc
al
es
 o
f I
nt
el
lig
en
ce
; I
Q
= 
In
te
lli
ge
nc
e 
Q
uo
tie
nt
; A
R
V
=A
nt
ire
tro
vi
ra
ls
J Dev Behav Pediatr. Author manuscript; available in PMC 2013 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Rice et al. Page 15
1 1
7 
ch
ild
re
n 
di
d 
no
t r
ep
or
t r
ac
e;
 3
 c
hi
ld
re
n 
di
d 
no
t r
ep
or
t t
he
ir 
et
hn
ic
ity
; 1
3 
ca
re
gi
ve
rs
 d
id
 n
ot
 re
po
rt 
th
ei
r i
nc
om
e;
 1
06
 c
hi
ld
re
n 
w
er
e 
m
is
si
ng
 th
ei
r c
ar
eg
iv
er
's 
pe
rf
or
m
an
ce
 IQ
; A
R
T 
us
e 
du
rin
g 
pr
eg
na
nc
y
w
as
 u
nk
no
w
n 
fo
r 5
6 
ch
ild
re
n;
 1
 c
hi
ld
 d
id
 n
ot
 c
on
se
nt
 to
 sh
ar
e 
th
ei
r m
at
er
na
l A
R
T 
hi
st
or
y.
 P
er
ce
nt
ag
es
 a
re
 b
as
ed
 o
n 
to
ta
l s
am
pl
e.
2 P
-v
al
ue
 c
al
cu
la
te
d 
by
 F
is
he
r’
s E
xa
ct
 T
es
t f
or
 c
at
eg
or
ic
al
 v
ar
ia
bl
es
 a
nd
 b
y 
T-
Te
st
 fo
r c
on
tin
uo
us
 v
ar
ia
bl
es
.
J Dev Behav Pediatr. Author manuscript; available in PMC 2013 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Rice et al. Page 16
Ta
bl
e 
2
Pr
ev
al
en
ce
 o
f L
an
gu
ag
e 
Im
pa
irm
en
t b
y 
H
IV
 S
ta
tu
s a
nd
 D
em
og
ra
ph
ic
 C
ha
ra
ct
er
is
tic
s f
or
 4
37
 H
IV
-I
nf
ec
te
d 
or
 H
IV
-E
xp
os
ed
 b
ut
 U
ni
nf
ec
te
d 
C
hi
ld
re
n 
in
th
e 
A
do
le
sc
en
t M
as
te
r P
ro
to
co
l o
f t
he
 P
ed
ia
tri
c 
H
IV
/A
ID
S 
C
oh
or
t S
tu
dy
La
ng
ua
ge
 Im
pa
irm
en
t C
la
ss
ifi
ca
tio
n
C
ha
ra
ct
er
is
tic
1
Pr
im
ar
y
(N
=4
8)
C
on
cu
rr
en
t
(N
=1
05
)
N
on
e
(N
=2
84
)
T
ot
al
(N
=4
37
)
P-
V
al
ue
2
C
E
L
F 
Sc
or
e
M
ea
n 
(S
D
)
74
.2
 (9
.6
)
65
.8
 (1
2.
7)
98
.7
 (1
0.
3)
88
.1
 (1
8.
2)
<0
.0
01
H
IV
 S
ta
tu
s
H
IV
-I
nf
ec
te
d
29
 (1
0%
)
67
 (2
4%
)
18
8 
(6
6%
)
28
4
0.
71
H
IV
-E
xp
os
ed
, U
ni
nf
ec
te
d
19
 (1
2%
)
38
 (2
5%
)
96
 (6
3%
)
15
3
A
ge
 (y
ea
rs
)
M
ea
n 
(S
D
)
11
.8
 (2
.7
)
11
.8
 (2
.8
)
12
.2
 (2
.6
)
12
.0
 (2
.7
)
0.
33
7 
– 
8
11
 (1
5%
)
23
 (3
1%
)
40
 (5
4%
)
74
0.
25
9 
– 
12
19
 (1
0%
)
48
 (2
4%
)
13
3 
(6
7%
)
20
0
13
 –
 1
6
18
 (1
1%
)
34
 (2
1%
)
11
1 
(6
8%
)
16
3
B
ir
th
 Y
ea
r
B
ef
or
e 
19
95
14
 (1
1%
)
25
 (1
9%
)
92
 (7
0%
)
13
1
0.
27
19
95
–1
99
9
23
 (1
0%
)
57
 (2
5%
)
14
9 
(6
5%
)
22
9
20
00
 o
r L
at
er
11
 (1
4%
)
23
 (3
0%
)
43
 (5
6%
)
77
Se
x
M
al
e
27
 (1
2%
)
48
 (2
2%
)
14
6 
(6
6%
)
22
1
0.
45
Fe
m
al
e
21
 (1
0%
)
57
 (2
6%
)
13
8 
(6
4%
)
21
6
R
ac
e
W
hi
te
 o
r O
th
er
8 
(7
%
)
20
 (1
8%
)
81
 (7
4%
)
10
9
0.
06
B
la
ck
 o
r A
fr
ic
an
 A
m
er
ic
an
40
 (1
3%
)
79
 (2
5%
)
19
2 
(6
2%
)
31
1
E
th
ni
ci
ty
H
is
pa
ni
c 
or
 L
at
in
o
6 
(6
%
)
32
 (3
1%
)
65
 (6
3%
)
10
3
0.
04
N
ot
 H
is
pa
ni
c 
or
 L
at
in
o
42
 (1
3%
)
73
 (2
2%
)
21
6 
(6
5%
)
33
1
C
ar
eg
iv
er
 E
du
ca
tio
n
N
ot
 a
 H
S 
G
ra
du
at
e
10
 (1
0%
)
36
 (3
4%
)
59
 (5
6%
)
10
5
0.
02
A
t l
ea
st
 a
 H
S 
G
ra
du
at
e
38
 (1
1%
)
69
 (2
1%
)
22
5 
(6
8%
)
33
2
A
nn
ua
l H
ou
se
ho
ld
 In
co
m
e
≤ 2
0K
26
 (1
2%
)
57
 (2
6%
)
13
5 
(6
2%
)
21
8
0.
37
> 
20
K
21
 (1
0%
)
44
 (2
1%
)
14
1 
(6
8%
)
20
6
C
ar
eg
iv
er
 M
ar
ita
l S
ta
tu
s
M
ar
rie
d
14
 (9
%
)
36
 (2
2%
)
11
2 
(6
9%
)
16
2
0.
33
N
ot
 M
ar
rie
d
34
 (1
2%
)
69
 (2
5%
)
17
2 
(6
3%
)
27
5
C
ar
eg
iv
er
 is
 B
io
lo
gi
ca
l P
ar
en
t
J Dev Behav Pediatr. Author manuscript; available in PMC 2013 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Rice et al. Page 17
La
ng
ua
ge
 Im
pa
irm
en
t C
la
ss
ifi
ca
tio
n
C
ha
ra
ct
er
is
tic
1
Pr
im
ar
y
(N
=4
8)
C
on
cu
rr
en
t
(N
=1
05
)
N
on
e
(N
=2
84
)
T
ot
al
(N
=4
37
)
P-
V
al
ue
2
Y
es
25
 (1
0%
)
52
 (2
1%
)
16
6 
(6
8%
)
24
3
0.
25
N
o
23
 (1
2%
)
53
 (2
7%
)
11
8 
(6
1%
)
19
4
C
ar
eg
iv
er
's
 W
A
SI
 P
er
fo
rm
an
ce
 IQ N
40
68
22
3
33
1
M
ea
n 
(S
D
)
89
.8
 (1
3.
1)
87
.7
 (1
4.
2)
94
.0
 (1
4.
9)
92
.2
 (1
4.
7)
0.
00
4
Im
pa
irm
en
t (
IQ
<7
0)
2 
(1
3%
)
6 
(4
0%
)
7 
(4
7%
)
15
0.
12
N
o 
Im
pa
irm
en
t
38
 (1
2%
)
62
 (2
0%
)
21
6 
(6
8%
)
31
6
M
at
er
na
l A
R
V
 U
se
 In
 P
re
gn
an
cy
Y
es
17
 (9
%
)
49
 (2
7%
)
11
4 
(6
3%
)
18
0
0.
39
N
o
26
 (1
3%
)
45
 (2
3%
)
12
9 
(6
5%
)
20
0
C
EL
F=
 C
lin
ic
al
 E
va
lu
at
io
n 
of
 L
an
gu
ag
e 
Fu
nc
tio
ni
ng
; W
A
SI
=W
ec
hs
le
r A
du
lt 
Sc
al
es
 o
f I
nt
el
lig
en
ce
; I
Q
= 
In
te
lli
ge
nc
e 
Q
uo
tie
nt
; A
R
V
=A
nt
ire
tro
vi
ra
ls
; H
S=
hi
gh
 sc
ho
ol
1 1
7 
ch
ild
re
n 
di
d 
no
t r
ep
or
t t
he
ir 
ra
ce
; 3
 c
hi
ld
re
n 
di
d 
no
t r
ep
or
t t
he
ir 
et
hn
ic
ity
; 1
3 
ca
re
gi
ve
rs
 d
id
 n
ot
 re
po
rt 
th
ei
r h
ou
se
ho
ld
 in
co
m
e;
 1
06
 c
hi
ld
re
n 
w
er
e 
m
is
si
ng
 th
ei
r c
ar
eg
iv
er
's 
pe
rf
or
m
an
ce
 IQ
; A
R
T 
us
e
du
rin
g 
pr
eg
na
nc
y 
w
as
 u
nk
no
w
n 
fo
r 5
6 
ch
ild
re
n,
 a
nd
 1
 c
hi
ld
 d
id
 n
ot
 c
on
se
nt
 to
 sh
ar
e 
th
ei
r m
at
er
na
l A
R
T 
hi
st
or
y.
 P
er
ce
nt
ag
es
 a
re
 b
as
ed
 o
n 
to
ta
l s
am
pl
e 
an
d 
di
sp
la
y 
th
e 
pr
ev
al
en
ce
 o
f P
ri-
LI
, C
on
-L
I a
nd
 n
o
LI
 w
ith
in
 e
ac
h 
ch
ar
ac
te
ris
tic
.
2 P
-v
al
ue
 c
al
cu
la
te
d 
us
in
g 
Fi
sh
er
’s
 E
xa
ct
 T
es
t f
or
 c
at
eg
or
ic
al
 v
ar
ia
bl
es
 a
nd
 b
y 
an
al
ys
is
 o
f v
ar
ia
nc
e 
fo
r c
om
pa
ris
on
 o
f m
ea
ns
 fo
r c
on
tin
uo
us
 v
ar
ia
bl
es
.
J Dev Behav Pediatr. Author manuscript; available in PMC 2013 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Rice et al. Page 18
Ta
bl
e 
3
H
IV
 D
is
ea
se
 M
ar
ke
rs
, C
ur
re
nt
 A
nt
ire
tro
vi
ra
l (
A
R
T)
 R
eg
im
en
, a
nd
 A
R
T 
H
is
to
ry
 b
y 
La
ng
ua
ge
 Im
pa
irm
en
t C
at
eg
or
y 
fo
r 2
84
 H
IV
-I
nf
ec
te
d 
C
hi
ld
re
n 
in
 th
e
A
do
le
sc
en
t M
as
te
r P
ro
to
co
l o
f t
he
 P
ed
ia
tri
c 
H
IV
/A
ID
S 
C
oh
or
t S
tu
dy
L
an
gu
ag
e 
Im
pa
ir
m
en
t
C
ha
ra
ct
er
is
tic
1
Pr
im
ar
y
(N
 =
 2
9)
C
on
cu
rr
en
t
(N
 =
 6
7)
N
on
e
(N
 =
 1
88
)
T
ot
al
(N
 =
 2
84
)
P-
V
al
ue
2
H
IV
 V
ir
al
 L
oa
d 
> 
40
0 
co
pi
es
/m
L
3 
(1
0%
)
31
 (4
6%
)
46
 (2
4%
)
80
 (2
8%
)
<0
.0
01
C
D
4%
 <
 2
5%
3 
(1
0%
)
22
 (3
3%
)
35
 (1
8%
)
60
 (2
1%
)
0.
02
C
D
C
 C
la
ss
 C
3 
(1
0%
)
29
 (4
3%
)
45
 (2
4%
)
77
 (2
7%
)
0.
00
1
N
ad
ir
 C
D
4%
 ≥2
5%
10
 (3
4%
)
14
 (2
1%
)
51
 (2
7%
)
75
 (2
6%
)
0.
36
Pe
ak
 lo
g 1
0 H
IV
 R
N
A
 (c
op
ie
s/
m
L
)
 
 
M
ea
n 
(S
D
)
5.
2 
(1
.1
)
5.
6 
(0
.7
)
5.
3 
(0
.8
)
5.
4 
(0
.8
)
0.
00
4
D
ur
at
io
n 
on
 H
A
A
R
T
 
 
M
ea
n 
(S
D
)
9.
5 
(2
.6
)
9.
4 
(2
.8
)
8.
7 
(2
.9
)
9.
0 
(2
.9
)
0.
12
 
 
≤ 5
 y
ea
rs
2 
(7
%
)
8 
(1
2%
)
29
 (1
5%
)
39
 (1
4%
)
0.
47
A
ge
 a
t A
R
T
 In
iti
at
io
n
 
 
M
ea
n 
(S
D
)
2.
1 
(2
.0
)
1.
0 
(1
.6
)
1.
7 
(2
.0
)
1.
6 
(1
.9
)
0.
01
 
 
B
ef
or
e 
6 
m
on
th
s
6 
(2
1%
)
37
 (5
5%
)
71
 (3
8%
)
11
4 
(4
0%
)
0.
00
4
A
R
T
 r
eg
im
en
0.
83
 
 
H
A
A
R
T 
w
/ P
I
23
 (7
9%
)
46
 (6
9%
)
13
6 
(7
2%
)
20
5 
(7
2%
)
 
 
H
A
A
R
T 
w
/o
 P
I
4 
(1
4%
)
11
 (1
6%
)
32
 (1
7%
)
47
 (1
7%
)
 
 
N
on
-H
A
A
R
T 
A
R
T
0 
(0
%
)
4 
(6
%
)
9 
(5
%
)
13
 (5
%
)
A
R
T=
A
nt
ire
tro
vi
ra
l T
he
ra
py
; H
A
A
R
T=
H
ig
hl
y 
A
ct
iv
e 
A
R
T,
 d
ef
in
ed
 a
s a
t l
ea
st
 2
 A
R
V
 d
ru
gs
 fr
om
 a
t l
ea
st
 2
 d
ru
g 
cl
as
se
s, 
PI
=P
ro
te
as
e 
In
hi
bi
to
r; 
SD
=s
ta
nd
ar
d 
de
vi
at
io
n;
 C
D
C
=C
en
te
rs
 fo
r D
is
ea
se
 C
on
tro
l
an
d 
Pr
ev
en
tio
n
1 C
D
4 
an
d 
vi
ra
l l
oa
d 
m
ea
su
re
m
en
t c
lo
se
st
 to
 th
e 
tim
e 
of
 th
e 
C
EL
F 
ad
m
in
is
tra
tio
n 
w
er
e 
us
ed
. O
ne
 c
hi
ld
 d
id
 n
ot
 g
iv
e 
pe
rm
is
si
on
 to
 sh
ar
e 
th
ei
r A
R
T 
hi
st
or
y;
 1
 c
hi
ld
 w
as
 n
ev
er
 o
n 
A
R
Ts
; 1
2 
ch
ild
re
n 
w
er
e
ne
ve
r o
n 
H
A
A
R
T;
 1
8 
ch
ild
re
n 
w
er
e 
no
t o
n 
A
R
Ts
 a
t t
he
 ti
m
e 
of
 th
e 
C
EL
F 
ad
m
in
is
tra
tio
n.
 P
er
ce
nt
ag
es
 a
re
 b
as
ed
 o
n 
to
ta
l s
am
pl
e.
2 P
-v
al
ue
 c
al
cu
la
te
d 
by
 F
is
he
r’
s E
xa
ct
 T
es
t f
or
 c
at
eg
or
ic
al
 v
ar
ia
bl
es
 a
nd
 b
y 
an
al
ys
is
 o
f v
ar
ia
nc
e 
fo
r c
om
pa
ris
on
 o
f m
ea
ns
 fo
r c
on
tin
uo
us
 v
ar
ia
bl
es
.
J Dev Behav Pediatr. Author manuscript; available in PMC 2013 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Rice et al. Page 19
Ta
bl
e 
4
Lo
gi
st
ic
 R
eg
re
ss
io
n 
M
od
el
s o
f P
rim
ar
y 
La
ng
ua
ge
 Im
pa
irm
en
t v
s. 
N
o 
La
ng
ua
ge
 Im
pa
irm
en
t A
m
on
g 
A
ll 
C
hi
ld
re
n 
an
d 
W
ith
in
 H
IV
-I
nf
ec
te
d 
C
hi
ld
re
n
U
ni
va
ri
at
e 
L
og
is
tic
R
eg
re
ss
io
n 
M
od
el
s
Fi
na
l A
dj
us
te
d 
L
og
is
tic
R
eg
re
ss
io
n 
M
od
el
N
O
dd
s
R
at
io
95
%
C
on
fid
en
ce
In
te
rv
al
P-
va
lu
e
A
dj
us
te
d
O
dd
s R
at
io
95
%
C
on
fid
en
ce
In
te
rv
al
P-
va
lu
e
O
ve
ra
ll 
Sa
m
pl
e 
(H
IV
+ 
an
d 
H
E
U
)
H
IV
 S
ta
tu
s (
H
IV
+ 
vs
 H
EU
)
33
2
0.
78
(0
.4
2,
 1
.4
6)
0.
44
0.
75
(0
.4
0,
 1
.4
1)
0.
37
B
la
ck
 R
ac
e
33
2
2.
40
(1
.0
8,
 5
.3
2)
0.
03
2.
43
(1
.0
9,
 5
.4
3)
0.
03
A
ge
 ≥ 
13
 y
ea
rs
33
2
0.
94
(0
.5
0,
 1
.7
6)
0.
84
-
B
irt
h 
Y
ea
r (
vs
 1
99
5–
19
99
)
33
2
0.
41
 B
ef
or
e 
19
95
0.
99
(0
.4
8,
 2
.0
1)
0.
97
-
 2
00
0 
an
d 
La
te
r
1.
66
(0
.7
5,
 3
.6
7)
0.
21
-
M
al
e
33
2
1.
22
(0
.6
6,
 2
.2
5)
0.
54
-
H
is
pa
ni
c 
Et
hn
ic
ity
32
9
0.
47
(0
.1
9,
 1
.1
7)
0.
10
-
C
ar
eg
iv
er
 n
ot
 H
S 
G
ra
du
at
e
33
2
1.
00
(0
.4
7,
 2
.1
3)
0.
99
-
H
ou
se
ho
ld
 In
co
m
e 
≤ 2
0K
32
3
1.
29
(0
.6
9,
 2
.4
1)
0.
42
-
C
ar
eg
iv
er
 M
ar
rie
d
33
2
0.
63
(0
.3
2,
 1
.2
3)
0.
18
-
C
ar
eg
iv
er
 is
 B
io
lo
gi
ca
l P
ar
en
t
33
2
0.
77
(0
.4
2,
 1
.4
3)
0.
41
-
C
ar
eg
iv
er
 P
IQ
 <
 7
01
33
2
1.
62
(0
.3
3,
 8
.1
2)
0.
56
-
A
R
V
s d
ur
in
g 
Pr
eg
na
nc
y1
33
2
0.
74
(0
.3
8,
 1
.4
3)
0.
37
-
H
IV
+ 
Y
ou
th
2
H
IV
 V
ira
l l
oa
d 
> 
40
0 
co
pi
es
/m
L
21
7
0.
36
(0
.1
0,
 1
.2
3)
0.
10
0.
36
(0
.1
0,
 1
.2
5)
0.
11
C
D
C
 C
la
ss
 C
21
7
0.
37
(0
.1
1,
 1
.2
7)
0.
11
0.
37
(0
.1
1,
 1
.3
0)
0.
12
A
ge
 a
t A
R
T 
In
iti
at
io
n 
≤ 6
 m
o
21
5
0.
42
(0
.1
6,
 1
.0
9)
0.
07
0.
38
(0
.1
5,
 0
.9
9)
0.
05
C
D
4%
 <
 2
5%
21
7
0.
50
(0
.1
4,
 1
.7
6)
0.
28
-
Pe
ak
 V
ira
l L
oa
d 
> 
75
0,
00
0 
co
pi
es
/m
L
21
7
1.
04
(0
.3
4,
 3
.2
5)
0.
94
-
N
ad
ir 
C
D
4%
 ≥ 
25
%
21
7
1.
41
(0
.6
2,
 3
.2
4)
0.
41
-
D
ur
at
io
n 
on
 H
A
A
R
T 
≤ 5
 y
rs
20
6
0.
41
(0
.0
9,
 1
.8
4)
0.
25
-
J Dev Behav Pediatr. Author manuscript; available in PMC 2013 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Rice et al. Page 20
U
ni
va
ri
at
e 
L
og
is
tic
R
eg
re
ss
io
n 
M
od
el
s
Fi
na
l A
dj
us
te
d 
L
og
is
tic
R
eg
re
ss
io
n 
M
od
el
N
O
dd
s
R
at
io
95
%
C
on
fid
en
ce
In
te
rv
al
P-
va
lu
e
A
dj
us
te
d
O
dd
s R
at
io
95
%
C
on
fid
en
ce
In
te
rv
al
P-
va
lu
e
R
eg
im
en
 (v
s H
A
A
R
T 
w
ith
 P
I)
21
6
0.
75
  H
A
A
R
T 
w
ith
ou
t P
I
0.
74
(0
.2
4,
 2
.2
9)
0.
60
-
  N
on
-H
A
A
R
T 
or
 N
o 
A
R
T
0.
62
(0
.1
4,
 2
.8
5)
0.
54
-
PI
=P
ro
te
as
e 
In
hi
bi
to
r; 
SD
=s
ta
nd
ar
d 
de
vi
at
io
n;
 C
D
C
=C
en
te
rs
 fo
r D
is
ea
se
 C
on
tro
l a
nd
 P
re
ve
nt
io
n
1 M
is
si
ng
 d
at
a 
in
di
ca
to
r m
et
ho
d 
us
ed
 in
 th
is
 m
od
el
.
2 F
in
al
 a
dj
us
te
d 
m
od
el
 w
as
 n
ot
 a
dj
us
te
d 
fo
r a
ny
 d
em
og
ra
ph
ic
 fa
ct
or
s.
J Dev Behav Pediatr. Author manuscript; available in PMC 2013 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Rice et al. Page 21
Ta
bl
e 
5
Lo
gi
st
ic
 R
eg
re
ss
io
n 
M
od
el
s o
f C
on
cu
rr
en
t L
an
gu
ag
e 
Im
pa
irm
en
t v
s. 
N
o 
La
ng
ua
ge
 Im
pa
irm
en
t A
m
on
g 
A
ll 
C
hi
ld
re
n 
an
d 
W
ith
in
 H
IV
-I
nf
ec
te
d 
C
hi
ld
re
n
U
ni
va
ri
at
e 
L
og
is
tic
R
eg
re
ss
io
n 
M
od
el
s
Fi
na
l A
dj
us
te
d 
L
og
is
tic
R
eg
re
ss
io
n 
M
od
el
 (N
 =
 3
86
)
N
O
dd
s
R
at
io
95
%
C
on
fid
en
ce
In
te
rv
al
P-
va
lu
e
A
dj
us
te
d
O
dd
s
R
at
io
95
%
C
on
fid
en
ce
In
te
rv
al
P-
va
lu
e
O
ve
ra
ll 
Sa
m
pl
e 
(H
IV
+ 
an
d 
H
E
U
)
H
IV
 S
ta
tu
s (
H
IV
+ 
vs
 H
EU
)
38
9
0.
90
(0
.5
6,
 1
.4
4)
0.
66
0.
86
(0
.5
0,
 1
.5
0)
0.
60
A
ge
 ≥ 
13
 y
ea
rs
38
9
0.
75
(0
.4
6,
 1
.2
0)
0.
23
-
B
irt
h 
Y
ea
r (
vs
 1
99
5–
19
99
)
38
9
0.
14
0.
11
 B
ef
or
e 
19
95
0.
71
(0
.4
2,
 1
.2
2)
0.
21
0.
65
(0
.3
6,
 1
.1
5)
0.
14
 2
00
0 
an
d 
La
te
r
1.
40
(0
.7
7,
 2
.5
3)
0.
27
1.
42
(0
.7
5,
 2
.6
7)
0.
28
M
al
e
38
9
0.
80
(0
.5
1,
 1
.2
5)
0.
32
-
B
la
ck
 R
ac
e
38
9
1.
46
(0
.8
8,
 2
.4
2)
0.
15
3.
66
(1
.5
7,
 8
.5
5)
0.
00
3
H
is
pa
ni
c 
Et
hn
ic
ity
38
6
1.
46
(0
.8
8,
 2
.4
0)
0.
14
3.
16
(1
.3
5,
 7
.3
7)
0.
01
C
ar
eg
iv
er
 n
ot
 H
S 
G
ra
du
at
e
38
9
1.
99
(1
.2
1,
 3
.2
6)
0.
01
1.
77
(1
.0
3,
 3
.0
2)
0.
04
H
ou
se
ho
ld
 In
co
m
e 
≤ 2
0K
37
7
1.
35
(0
.8
6,
 2
.1
4)
0.
20
-
C
ar
eg
iv
er
 M
ar
rie
d
38
9
0.
80
(0
.5
0,
 1
.2
8)
0.
35
-
C
ar
eg
iv
er
 is
 B
io
lo
gi
ca
l P
ar
en
t
38
9
0.
70
(0
.4
4,
 1
.0
9)
0.
12
0.
54
(0
.3
2,
 0
.9
2)
0.
02
C
ar
eg
iv
er
 P
IQ
 <
 7
01
38
9
2.
99
(0
.9
7,
 9
.2
1)
0.
06
3.
25
(0
.9
9,
 1
0.
66
)
0.
05
A
R
V
s d
ur
in
g 
Pr
eg
na
nc
y1
38
9
1.
23
(0
.7
6,
 1
.9
8)
0.
39
-
H
IV
+ 
Y
ou
th
2
H
IV
 V
ira
l L
oa
d 
> 
40
0 
cp
/m
l
25
5
2.
66
(1
.4
8,
 4
.7
7)
0.
00
1
3.
04
(1
.5
7,
 5
.8
7)
<0
.0
01
C
D
C
 C
la
ss
 C
25
5
2.
43
(1
.3
5,
 4
.3
7)
0.
00
3
2.
19
(1
.1
4,
 4
.2
2)
0.
02
A
ge
 a
t A
R
T 
In
iti
at
io
n 
≤ 6
 m
o
25
3
2.
00
(1
.1
4,
 3
.5
2)
0.
02
2.
12
(1
.1
3,
 3
.9
7)
0.
02
C
D
4%
 <
 2
5%
25
5
2.
14
(1
.1
4,
 4
.0
1)
0.
02
-
Pe
ak
 V
ira
l L
oa
d 
>7
50
,0
00
 c
p/
m
l
25
5
1.
72
(0
.8
4,
 3
.5
5)
0.
14
-
N
ad
ir 
C
D
4%
 ≥ 
25
%
25
5
0.
71
(0
.3
6,
 1
.3
9)
0.
32
-
D
ur
at
io
n 
on
 H
A
A
R
T 
≤ 5
 y
rs
24
4
0.
73
(0
.3
1,
 1
.6
8)
0.
46
-
J Dev Behav Pediatr. Author manuscript; available in PMC 2013 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Rice et al. Page 22
U
ni
va
ri
at
e 
L
og
is
tic
R
eg
re
ss
io
n 
M
od
el
s
Fi
na
l A
dj
us
te
d 
L
og
is
tic
R
eg
re
ss
io
n 
M
od
el
 (N
 =
 3
86
)
N
O
dd
s
R
at
io
95
%
C
on
fid
en
ce
In
te
rv
al
P-
va
lu
e
A
dj
us
te
d
O
dd
s
R
at
io
95
%
C
on
fid
en
ce
In
te
rv
al
P-
va
lu
e
R
eg
im
en
 (v
s H
A
A
R
T 
w
/P
I)
25
4
0.
58
  H
A
A
R
T 
w
/o
 P
I
1.
02
(0
.4
7,
 2
.1
8)
0.
97
-
  N
on
-H
A
A
R
T 
or
 n
o 
A
R
T
1.
56
(0
.6
7,
 3
.5
9)
0.
30
-
H
S=
H
ig
h 
Sc
ho
ol
, H
A
A
R
T=
H
ig
hl
y 
A
ct
iv
e 
A
nt
ire
tro
vi
ra
l T
he
ra
py
, P
I=
Pr
ot
ea
se
 In
hi
bi
to
r, 
C
D
C
=C
en
te
rs
 fo
r D
is
ea
se
 C
on
tro
l a
nd
 P
re
ve
nt
io
n,
 P
IQ
=P
er
fo
rm
an
ce
 IQ
1 M
is
si
ng
 d
at
a 
in
di
ca
to
r m
et
ho
d 
us
ed
 in
 th
is
 m
od
el
.
2 F
in
al
 a
dj
us
te
d 
m
od
el
 w
as
 a
ls
o 
ad
ju
st
ed
 fo
r m
al
es
 v
s f
em
al
es
 (a
O
R
 =
 0
.5
2,
 p
 =
 0
.0
5)
, B
la
ck
 ra
ce
 (a
O
R
 =
 3
.0
, p
 =
 0
.0
2)
, l
ow
 c
ar
eg
iv
er
’s
 e
du
ca
tio
n 
(a
O
R
 =
 2
.2
, p
 =
 0
.0
3)
, a
nd
 b
io
lo
gi
ca
l p
ar
en
t a
s c
ar
eg
iv
er
(a
O
R
 =
 0
.5
3,
 p
 =
 0
.0
6)
.
J Dev Behav Pediatr. Author manuscript; available in PMC 2013 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Rice et al. Page 23
Ta
bl
e 
6
Li
ne
ar
 re
gr
es
si
on
 m
od
el
s f
or
 th
e 
co
nt
in
uo
us
 C
EL
F 
sc
or
e,
 a
dj
us
te
d 
fo
r o
th
er
 c
ov
ar
ia
te
s a
s n
ee
de
d,
 fo
r a
ll 
su
bj
ec
ts
 a
nd
 re
st
ric
te
d 
to
 H
IV
+ 
su
bj
ec
ts
N
A
dj
us
te
d 
L
in
ea
r 
R
eg
re
ss
io
n 
M
od
el
s,
w
ith
ou
t c
hi
ld
’s
 c
og
ni
tiv
e 
im
pa
ir
m
en
t
A
dj
us
te
d 
L
in
ea
r 
R
eg
re
ss
io
n
M
od
el
s, 
w
ith
 c
hi
ld
’s
 c
og
ni
tiv
e
im
pa
ir
m
en
t
A
dj
us
te
d
m
ea
n 
di
ffe
re
nc
e
95
%
 C
I
P-
va
lu
e
A
dj
us
te
d
m
ea
n 
di
ffe
re
nc
e
95
%
 C
I
P-
va
lu
e
O
ve
ra
ll 
Sa
m
pl
e 
(H
IV
+ 
an
d 
H
E
U
)
H
IV
 S
ta
tu
s (
H
IV
+ 
vs
 H
EU
)
43
7
0.
44
(−3
.2
0,
 4
.0
8)
0.
81
0.
79
(−2
.3
3,
 3
.9
1)
0.
62
B
la
ck
 R
ac
e
43
7
−6
.29
(−1
0.
14
, −
2.
43
)
0.
00
2
−4
.14
(−7
.4
5,
 −0
.8
3)
0.
01
C
ar
eg
iv
er
 n
ot
 H
S 
G
ra
du
at
e
43
7
−4
.86
(−8
.9
7,
 −0
.7
2)
0.
02
−4
.28
(−7
.7
9,
 −0
.7
7)
0.
02
H
ou
se
ho
ld
 In
co
m
e 
≤ 2
0K
42
4
−3
.39
(−6
.9
4,
 0
.1
5)
0.
06
−1
.63
(−4
.6
7,
 1
.4
1)
0.
29
C
ar
eg
iv
er
 P
IQ
 <
 7
01
43
7
−1
0.0
1
(−1
9.
31
, −
0.
71
)
0.
04
−6
.85
(−1
4.
72
, 1
.0
1)
0.
09
C
hi
ld
’s
 c
og
ni
tiv
e 
im
pa
irm
en
t
41
3
--
-
--
-
--
-
−2
0.0
2
(−2
3.
16
, −
16
.8
9)
<0
.0
01
H
IV
+ 
Y
ou
th
H
IV
 V
ira
l L
oa
d 
> 
40
0 
cp
/m
l
28
4
−5
.76
(−1
0.
36
, −
1.
15
)
0.
02
−4
.80
(−8
.8
2,
 −0
.7
8)
0.
02
C
D
C
 C
la
ss
 C
28
4
−4
.30
(−1
0.
36
, −
1.
15
)
0.
07
−1
.30
(−5
.4
1,
 2
.8
0)
0.
53
B
la
ck
 R
ac
e
28
4
−8
.71
(−1
3.
52
, −
3.
90
)
<0
.0
01
−4
.77
(−9
.0
0,
 −0
.4
3)
0.
03
C
ar
eg
iv
er
 n
ot
 H
S 
G
ra
du
at
e
28
4
−6
.92
(−1
1.
86
, −
1.
98
)
0.
01
−5
.53
(−9
.7
9,
 −1
.2
7)
0.
01
C
hi
ld
’s
 c
og
ni
tiv
e 
im
pa
irm
en
t
27
7
--
-
--
-
--
-
−1
9.1
4
(−2
3.
08
, −
15
.2
0)
<0
.0
01
H
EU
=H
IV
-e
xp
os
ed
 u
ni
nf
ec
te
d;
 H
S=
hi
gh
 sc
ho
ol
; C
D
C
=C
en
te
rs
 fo
r D
is
ea
se
 C
on
tro
l a
nd
 P
re
ve
nt
io
n;
 P
IQ
=P
er
fo
rm
an
ce
 IQ
 S
co
re
 fr
om
 th
e 
W
ec
hs
le
r A
du
lt 
Sc
al
es
 o
f I
nt
el
lig
en
ce
1 M
is
si
ng
 d
at
a 
in
di
ca
to
r m
et
ho
d 
us
ed
 in
 th
is
 m
od
el
.
J Dev Behav Pediatr. Author manuscript; available in PMC 2013 February 1.
